GMAB vs SRPT vs ABBV vs RGEN vs PFE

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus -82. 7% for Genmab A/S (GMAB). Genmab A/S (GMAB) offers the better valuation at 17. 6x trailing P/E (23. 0x forward), making it the more compelling value choice. Analysts rate Genmab A/S (GMAB) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 17.

6x versus Repligen Corporation at 147. 0x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: RGEN returned +358. 2% versus SRPT's +13. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus Sarepta Therapeutics, Inc. 's 1. 95β — meaning SRPT is approximately 606% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Repligen Corporation (RGEN) carries a lower debt/equity ratio of 33% versus 93% for Genmab A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus -82. 7% for Genmab A/S (GMAB). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Genmab A/S (GMAB) is the more profitable company, earning 25.

9% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 25. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 33. 6% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — GMAB leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 5. 9x forward P/E versus 61. 7x for Repligen Corporation — 55. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMAB: 40. 0% to $37. 88.

In this comparison, PFE (6.

5% yield), ABBV (3. 2% yield) pay a dividend. GMAB, SRPT, RGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 2% yield, +293. 8% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +293. 8%, SRPT: +13. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GMAB is a mid-cap deep-value stock; SRPT is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; RGEN is a small-cap high-growth stock; PFE is a mid-cap income-oriented stock. ABBV, PFE pay a dividend while GMAB, SRPT, RGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.